BioCryst Pharmaceuticals Inc. (BCRX), a biotechnology company, announcing preliminary results of a Phase II study of intravenous peramivir for the treatment of seasonal influenza said Monday the study met its primary endpoint.
The primary endpoint was the improvement in the median time to alleviation of symptoms in subjects with confirmed, acute, uncomplicated influenza infection, compared to placebo alone. The result was highly statistically significant, BioCryst noted. BioCryst's partner Shionogi & Co., Ltd. conducted the trial in Japan.
Peramivir was administered via a single dose injection in the outpatient setting, and the trial enrolled 300 subjects who had a positive rapid antigen test indicating acute influenza illness.
"We are encouraged by the positive results of this Phase II study testing a single dose of i.v. peramivir in the outpatient setting," stated Jon Stonehouse, president and chief executive officer of BioCryst.
Earlier this month, the Birmingham, Alabama-based BioCryst began a Phase II study of intra-muscular peramivir in the outpatient setting comparing a single 600 mg dose to placebo in the treatment of seasonal influenza.
Peramivir is being developed in Japan by Shionogi under an exclusive license from BioCryst, which received a $14 million up-front payment and may also receive future clinical event milestone payments up to $21 million and commercial event milestone payments up to $95 million in addition to double-digit - between 10% and 20% range - royalty payments on product sales of peramivir.
BioCryst noted that it retains all rights to commercialize peramivir in North America, Europe, and other countries outside of Japan and Korea.
BCRX is trading up $0.49 or 18.70% on a volume of nearly 336 thousand shares.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.